ABBV-444, REFRESH OPTIVE UD — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-08 (month) in 1mo
ESTIMATED |
READOUT
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear
Phase 3 · Dry Eye Disease |
ABBV AbbVie Inc. | ABBV-444, REFRESH OPTIVE UD |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|